Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 11, 2025. The filing details the outcomes of shareholder votes regarding director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Director Elections (Class I)
Two nominees were elected to serve three-year terms until the 2028 Annual Meeting:
- Daniel Barber: 36,060,882 votes For; 3,546,668 votes Against; 29,848,112 Broker Non-Votes.
- Timothy E. Morris: 35,562,599 votes For; 4,044,951 votes Against; 29,848,112 Broker Non-Votes.
Executive Compensation
The non-binding advisory proposal to approve executive compensation was approved.
- Votes For: 32,454,278
- Votes Against: 6,694,084
- Votes Abstaining: 459,188
- Broker Non-Votes: 29,848,112
Auditor Ratification
Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 66,530,646
- Votes Against: 1,166,766
- Votes Abstaining: 1,758,250
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the specific executive compensation plan details referenced in the advisory vote.
- Confirm the tenure and background of the newly elected Class I directors.
- Check for any subsequent filings regarding the implementation of the auditor ratification.